Clinical trial • Phase IV • Neurology
Clinical trial in Focal epilepsy
Phase IV trial for Focal epilepsy. None/Not specified-controlled. 60 participants.
Overview
- Trial Therapeutic Area
- Neurology
- Trial Disease
- Focal epilepsy
- Trial Stage
- Phase IV
Key dates
- Initial CTIS Submission Date
- 29-08-2024
- First CTIS Authorization Date
- 14-10-2024
Trial design
None/Not specified-controlled Phase IV trial across 1 site in Austria.
- Comparator
- None/Not specified
- Target Sample Size
- 60
Eligibility
Recruits 60 Vulnerable populations not selected; no details on consent or assent provided..
- Vulnerable Population
- Vulnerable populations not selected; no details on consent or assent provided.
Recruitment
- Planned Sample Size
- 60
- Recruitment Window Months
- 110
Geography
- Total Number Of Sites
- 1
- Total Number Of Participants
- 60
Austria
- Earliest CTIS Part Ii Submission Date
- 17-09-2024
- Latest Decision Or Authorization Date
- 14-10-2024
- Processing Time Days
- 27
- Number Of Sites
- 1
- Number Of Participants
- 60
Sites
- Site Name
- Medical University Of Vienna
- Department Name
- Department of Clinical Pharmacology
- Contact Person Name
- Markus Zeitlinger
- Contact Person Email
- markus.zeitlinger@meduniwien.ac.at
- Number Of Participants
- 60
Sponsor
Primary sponsor
- Full Name
- Medical University Of Vienna
- Organisation Type
- Educational Institution
- Country Of Registered Address
- Austria
Related trials
Other published trials that may interest you.
- PROBENECID for Focal epilepsy
- AZETUKALNER for Focal epilepsy
- OCRELIZUMAB for Relapsing multiple sclerosis | Relapsing-remitting multiple sclerosis | Secondary progressive multiple sclerosis (active)
- CENOBAMATE for Partial-onset (focal) seizures
- Ocrelizumab for Relapsing multiple sclerosis | Relapsing-remitting multiple sclerosis | Active secondary progressive multiple sclerosis